Paper Details

  1. Home
  2. Paper Details

Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.

Author: BrodskyMatthew, FactorStewart A, FoxSusan H, KnowlesNadine, LangAnthony E, MetmanLeonard Verhagen, NuttJohn G, PopeLaura E, SiffertJoão

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study investigated the safety and efficacy of dextromethorphan plus quinidine for treating levodopa-induced dyskinesia in Parkinson's disease. The drug combination acts as a sigma-1 receptor agonist and glutamatergic/monoaminergic modulator.
Paper Details　
Original Abstract of the Article :
Nondopaminergic pathways represent potential targets to treat levodopa-induced dyskinesia in Parkinson's disease (PD). This pilot-study (NCT01767129) examined the safety/efficacy of the sigma-1 receptor-agonist and glutamatergic/monoaminergic modulator, dextromethorphan plus quinidine (to inhibit ra...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/mds.26976

データ提供：米国国立医学図書館（NLM）

Trial of Dextromethorphan/Quinidine to Treat Levodopa-Induced Dyskinesia in Parkinson's Disease

This study delves into the complex world of Parkinson's disease, exploring the potential of a novel combination therapy to alleviate levodopa-induced dyskinesia, a debilitating side effect of the most common medication for Parkinson's. It's like searching for a hidden oasis in the vast desert of Parkinson's treatment - seeking out new and effective strategies to manage the symptoms of this challenging condition. The authors conducted a pilot study to evaluate the safety and efficacy of dextromethorphan plus quinidine for treating levodopa-induced dyskinesia, focusing on its potential to modulate nondopaminergic pathways involved in this condition.

A New Oasis in the Desert of Parkinson's Treatment

This study offers a glimmer of hope for individuals with Parkinson's disease who struggle with levodopa-induced dyskinesia. It's like discovering a hidden oasis in the desert - providing a potential solution for a challenging condition. The findings encourage further research into the therapeutic potential of dextromethorphan/quinidine and its potential to improve the lives of individuals with Parkinson's disease.

Navigating the Sands of Parkinson's Disease

This research provides valuable insights into the potential for new treatments for Parkinson's disease, offering a beacon of hope for individuals seeking relief from this debilitating condition. It's like having a guidebook for navigating a complex desert - helping to make informed decisions and achieve optimal outcomes. The study encourages further research into the therapeutic potential of dextromethorphan/quinidine and its potential to improve the lives of individuals with Parkinson's disease.

Dr.Camel's Conclusion

This pilot study explores the potential of dextromethorphan/quinidine for treating levodopa-induced dyskinesia in Parkinson's disease, offering a glimmer of hope in the desert of Parkinson's treatment. It's like discovering a new oasis - a potential solution for a challenging condition and empowering clinicians to make more informed decisions.
Date :
  1. Date Completed 2018-03-30
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

28370447

DOI: Digital Object Identifier

10.1002/mds.26976

Related Literature

Article Analysis
・Effects of dextromethorphan and quinidine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.